Is the "Common Cold" Our Greatest Ally in the Battle Against SARS-CoV-2?

被引:4
|
作者
Capoor, Manu N. [1 ,2 ]
Ahmed, Fahad S. [3 ]
McDowell, Andrew [4 ]
Slaby, Ondrej [5 ,6 ]
机构
[1] Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, 1230 York Ave, New York, NY 10021 USA
[2] MMF Syst Inc, Execut Off, New York, NY 10022 USA
[3] MyMedicalFiles MMF Syst Inc, Data Sci & Engn, New York, NY USA
[4] Ulster Univ, Sch Biomed Sci, Nutr Innovat Ctr Food & Hlth NICHE, Coleraine, Londonderry, North Ireland
[5] Masaryk Univ, Cent European Inst Technol CEITEC, Brno, Czech Republic
[6] Masaryk Univ, Dept Biol, Fac Med, Brno, Czech Republic
关键词
SARS-CoV-2; COVID-19; T-cell; human coronaviruses; immunity; contact tracing; children; COVID-19; CHILDREN;
D O I
10.3389/fcimb.2020.605334
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The discovery of T-cell responses to SARS-CoV-2 in non-infected individuals indicates cross-reactive immune memory from prior exposure to human coronaviruses (HCoV) that cause the common cold. This raises the possibility that "immunity" could exist within populations at rates that may be higher than serology studies estimate. Besides specialized research labs, however, there is limited ability to measure HCoV CD4+ and CD8+ T-cell responses to SARS-CoV-2 infection, which currently impedes interpretation of any potential correlation between COVID-19 disease pathogenesis and the calibration of pandemic control measures. Given this limited testing ability, an alternative approach would be to exploit the large cohort of currently available data from which statistically significant associations may be generated. This would necessitate the merging of several public databases including patient and contact tracing, which could be created by relevant public health organizations. Including data from both symptomatic and asymptomatic patients in SARS-CoV-2 databases and surveillance systems could provide the necessary information to allow for more informed decisions.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Potential Utility of Radiopharmaceuticals in the Battle Against SARS-Cov-2 and COVID-19 Pandemic
    Sager, Omer
    Dincoglan, Ferrat
    Demiral, Selcuk
    Beyzadeoglu, Murat
    CURRENT RADIOPHARMACEUTICALS, 2022, 15 (02) : 93 - 95
  • [22] PDZ2-conjugated-PLGA nanoparticles are tiny heroes in the battle against SARS-CoV-2
    Giacon, Noah
    Lo Cascio, Ettore
    Pennacchietti, Valeria
    De Maio, Flavio
    Santarelli, Giulia
    Sibilia, Diego
    Tiberio, Federica
    Sanguinetti, Maurizio
    Lattanzi, Wanda
    Toto, Angelo
    Arcovito, Alessandro
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [23] Intranasal administration of cold-adapted live-attenuated SARS-CoV-2 candidate vaccine confers protection against SARS-CoV-2
    Abdoli, Mohsen
    Shafaati, Maryam
    Ghamsari, Ladan Kazem
    Abdoli, Asghar
    VIRUS RESEARCH, 2022, 319
  • [24] Do We Need to Vaccinate Our Infants Against SARS-CoV-2 Infection?
    Soni, Vimlesh
    Jain, Suksham
    Gupta, Seema
    Chawla, Deepak
    Khurana, Supreet
    Singh, Kuldeep
    INDIAN JOURNAL OF PEDIATRICS, 2024, 91 (8): : 856 - 856
  • [25] Impfung gegen SARS-CoV-2 bei KrebspatientenVaccination against SARS-CoV-2 in cancer patients
    Marie von Lilienfeld-Toal
    Christina Rieger
    Nicola Giesen
    Bernhard Wörmann
    Der Onkologe, 2021, 27 : 691 - 696
  • [26] SARS-CoV-2 infection and cancer Evidence for and against a role of SARS-CoV-2 in cancer onset
    Stingi, Aureliano
    Cirillo, Luca
    BIOESSAYS, 2021, 43 (08)
  • [27] What SARS-CoV-2 does to our brains
    Aschman, Tom
    Mothes, Ronja
    Heppner, Frank L.
    Radbruch, Helena
    IMMUNITY, 2022, 55 (07) : 1159 - 1172
  • [28] Adaptive immunity against SARS-CoV-2
    Combadiere, Behazine
    M S-MEDECINE SCIENCES, 2020, 36 (10): : 908 - 913
  • [29] Timing vaccination against SARS-CoV-2
    Barnoud, Coline
    Wang, Chen
    Scheiermann, Christoph
    CELL RESEARCH, 2021, 31 (11) : 1146 - 1147
  • [30] Antiviral drugs against SARS-CoV-2
    Aiello, Tommaso Francesco
    Garcia-Vidal, Carolina
    Soriano, Alex
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2022, 35 : 10 - 15